Skip to content

Efficacy and safety of remazolam for sedation in elderly patients during gastroenteroscopy

Efficacy and safety of remazolam for sedation in elderly patients during gastroenteroscopy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200055828
Enrollment
Unknown
Registered
2022-01-20
Start date
2022-06-19
Completion date
Unknown
Last updated
2023-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive tract disease

Interventions

P group :Group P: Propofol 1.5-2mg/kg was intravenously induced, and then maintained with 1 mL /(kg·h) (diluted to 6 mg/ mL). Maintain BIS55-65.
R group :R group: Remazolam 0.15-0.2 mg/kg intravenous induction, followed by 0.8-1.2 ml/(kg·h) maintenance (diluted to 1 mg/ml). Maintain BIS 55 to 65

Sponsors

The First Affiliated Hospital Of Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing painless gastroenteroscopy; 2. Patients aged over 65 years old, no gender limitation; 3. Body mass index (BMI) 18-30kg /m2; 4. American Society of Anesthesiologists (ASA) grade I - III; 5. Clearly understand and voluntarily participate in the study, and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. With severe respiratory disease; 2. Suffer from mental illness; 3. Hepatic dysfunction; 4. Renal dysfunction.

Design outcomes

Primary

MeasureTime frame
Sedation success rate;

Countries

China

Contacts

Public ContactLiu Mei

The First Affiliated Hospital Of Nanchang University

376285286@qq.com+86 15079107578

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026